Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Patrick Connerty
The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia
CONFLICT OF INTEREST STATEMENT The authors declare no competing interests. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description bjh70596-sup-0001-Supinfo.docxWord 2007 document , 1.7 MB Data S1. Supplementary Methods. Figure S1. (A) Correlation between MIK665 and AMG176 IC50 in AML cell lines.
CRISPR-Cas9 Genome-Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies
1 Introduction Paediatric cancers represent a diverse set of diseases, with a large range of different histotypes that can be broadly grouped into three main categories: haematological cancers, brain tumours, and extracranial solid tumours. These collectively however represent less than 1% of annual documented cancer cases [1, 2], with an estimated 19 million new cases of adult cancer in 2020 alone [3], classifying paediatric cancer as a rare disease.
Immune‐deficient MISTRG mice support expansion of leukaemia‐initiating cells in xenograft models of paediatric acute myeloid leukaemia
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Supporting Information Filename Description bjh20029-sup-0001-supinfo.docxWord 2007 document , 10 MB Data S1. REFERENCES 1, , . Leukemic stem cells: identification and clinical application. Int J Hematol. 2017; 105(5): 549–557. 2, . Critical differences in hematopoiesis and lymphoid development between humans and mice. J Clin Immunol. 2013; 33(4): 711–715. 3, , , , , .
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis
Abstract Abnormal metabolism is a fundamental hallmark of cancer and represents a therapeutic opportunity, yet its regulation by oncogenes remains poorly understood. Here, we uncover that JMJD1C, a jumonji C (JmjC)-containing H3K9 demethylase, is a critical regulator of aberrant metabolic processes in homeobox A9 (HOXA9)-dependent acute myeloid leukemia (AML).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Patrick
Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack